About Kynurenine--oxoglutarate transaminase 1
Kynurenine--oxoglutarate transaminase 1 (KYAT1) is a protein
from Homo sapiens identified by UniProt accession
Q16773, 422 residues long.
MolForge cross-references it against 0 known binders and
66 disease associations.
Target properties
| Protein name | Kynurenine--oxoglutarate transaminase 1 |
| UniProt accession | Q16773 |
| Gene | KYAT1 |
| Organism | Homo sapiens |
| Length | 422 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (66)
Diseases linked to this target (Open Targets).
- mean platelet volume · score 0.18
- high density lipoprotein cholesterol measurement · score 0.06
- serum albumin measurement · score 0.06
- allergic disease · score 0.06
- attention deficit hyperactivity disorder · score 0.06
- Neurofibromatosis type 6 · score 0.05
- blood metabolite measurement · score 0.05
- Tourette syndrome · score 0.05
- attention deficit-hyperactivity disorder 8 · score 0.05
- schizophrenia 15 · score 0.05
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-Q16773-F1 | alphafold | PREDICTED | 97.86 | — |
Amino-acid sequence (422 residues)
MAKQLQARRL DGIDYNPWVE FVKLASEHDV VNLGQGFPDF PPPDFAVEAF QHAVSGDFML NQYTKTFGYP PLTKILASFF GELLGQEIDP LRNVLVTVGG YGALFTAFQA LVDEGDEVII IEPFFDCYEP MTMMAGGRPV FVSLKPGPIQ NGELGSSSNW QLDPMELAGK FTSRTKALVL NTPNNPLGKV FSREELELVA SLCQQHDVVC ITDEVYQWMV YDGHQHISIA SLPGMWERTL TIGSAGKTFS ATGWKVGWVL GPDHIMKHLR TVHQNSVFHC PTQSQAAVAE SFEREQLLFR QPSSYFVQFP QAMQRCRDHM IRSLQSVGLK PIIPQGSYFL ITDISDFKRK MPDLPGAVDE PYDRRFVKWM IKNKGLVAIP VSIFYSVPHQ KHFDHYIRFC FVKDEATLQA MDEKLRKWKV EL
Explore Kynurenine--oxoglutarate transaminase 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets